1 / 23

Teva overview

2012. Teva overview. Teva in a Glance. No. 1 global generic company A Top 15 global pharmaceutical company Producing 71 Billion tablets and capsules a year Operating in 60 countries Manufacturing in 74 production sites Distributing products to over 120 markets

paprika
Télécharger la présentation

Teva overview

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 2012 Teva overview

  2. Teva in a Glance No. 1global generic company A Top 15 global pharmaceutical company Producing 71 Billion tablets and capsules a year Operating in 60 countries Manufacturing in 74production sites Distributing products to over 120markets Employs46,000 people worldwide** Investing $80 million in environmental projects Presenting a global product portfolio of 1,300 molecules Featuring $18.3billion in sales and $4.4billion in net income* * Non GAAP, as for Dec. 2011 ** Employees as of Dec. 2011

  3. Starting out at 1901 in Jerusalem • Established by 3 young pharmacists selling drugs in a small store

  4. More than a century later… • We are among the top 15 pharmaceutical companies and the world leader in Generics

  5. Our Mission

  6. Our Operations • 71 Billion tablets and capsules - 74 production sites - 34 R&D centers

  7. 1.6 Global leadership - Keeping the gap 2011 Global Peer Group Sales $18.3 B $9.5 B $5.6 B $3.7 B $2.2 B $2.1 B $1.7 B Source: First Call and Company filings

  8. Top Global Markets US No. 1 with ~18% market share in world’s largest market Germany No. 1 with ~22% market share Japan No. 3 with ~11% market share Russia No. 1 with ~10.5% generic market share No. 4 in overall Russian Pharma Market Canada No.1 with ~25% market share

  9. Strong Growth Track Record Sales Net income* Operations Plants** Employees** Market cap** $BN $Mil Countries Numbers Thousand $BN 46 39 18.3 4,438 60 56 30 21 18 8.7 9.6 1.7 6 2.5 148 0.3 0.3 19 1990 2000 2011 1990 2000 2011 1990 2000 2011 1990 2000 2011 1990 2000 2011 1990 2000 2011 *2011 Net income - Non-GAAP ** Market cap, Employees and Plants as of Dec 31st 2011

  10. Strong M&A track record Strong M&A track record Index, 1995=100 CAGR of 21.5% CAGR of 30% CoGenesys Sales Net income* Infarmassa US / biopharma Peru Bentley ratiopharm Theramex Spain Europe Europe- WH Barr Tayio & TK Sicor Pharmachemie Global Japan Global Netherlands Cephalon Medilac (50%) JK USA Turkey APS / Berk India / API PGT Ivax UK Global Global Biocraft Novopharm HPFC US Canada, Hungary Italy Bayer Classics Copley Dorom Biogal France US Italy Hungary Pharbil ICI Netherlands Italy * Non GAAP

  11. Financial Growth • More then 10 years of 2 digits growth in sales every year * Operating income and net income are non-GAAP results

  12. Towards The Future

  13. Diversifying Our Geographies Sales 2011 = $18.3BN Sales 2010 = $16.1BN 14% International 21% International 48% North America 62% North America 24% Europe 31% Europe

  14. Diversifying Our Business GENERICS Ratiopharm: GX #1 in Europe EMIAorganic growth: 14% driven primarily by Russia Latin America organic growth: 15% Taiyo: A leading player in Japan Infarmasa: expansion in Latin America BRANDED Multi Faceted Business Progress on all fronts Cephalon: diversification of our branded business Theramex: global expansion of our women’s health platform OTC JV with P&G: leverage value in existing OTC business Biologics Pipelinecreated JV with Lonza Ratiopharmknow how and products

  15. Still Room for Growth in Generics? $135-150 BN in 2015 GROWTH GROWTH GROWTH GROWTH Increasing opportunities in emerging generics markets People livinglonger and consuming more drugs Healthcare reforms and cost saving initiatives $150bn of brands going off-patentin the next5 years

  16. Teva Branded - Multifaceted approach & expertise 2010 Revenue: $4.9B 2012 Revenue: $8.2B (Estimated) 2011 Revenue: $6.5B • Biosimilars • Women’s Health • CNS • Biosimilars • Women’s Health • Copaxone Azilect • Respiratory • Oncology • Respiratory • New Product Licensing • InnovativePipeline • Pain • Innovative Pipeline • New Product Licensing 2015 2010

  17. Teva Expending Branded Business

  18. The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry

  19. Teva in Israel

  20. Teva Israel and Shoham logistic center • 12 sites in Israel, producing 30% of Teva’s production in the world

  21. Grow with the best – Teva’s workforce • 7,150 employees - adding 4,300 people to workforce in 10 Years

  22. Kfar Sava new R&D center • More than 850 generic and innovative R&D staff In Israel

More Related